本文選題：CAR-T細(xì)胞 + 設(shè)計(jì)策略�。� 參考：《中國腫瘤生物治療雜志》2017年05期

【摘要】：嵌合抗原受體T(chimeric antigen receptor T cells,CAR-T)細(xì)胞已從實(shí)驗(yàn)室走向了臨床試驗(yàn),在治療B細(xì)胞惡性腫瘤中取得了顯著療效,但在探索CAR-T細(xì)胞治療惡性腫瘤的臨床研究中,仍面臨不少困難與挑戰(zhàn):難以找到腫瘤特異性的靶點(diǎn),以克服其脫靶效應(yīng)(on-target off tumor effect);在治療實(shí)體瘤中CAR-T細(xì)胞很難達(dá)到腫瘤部位,以改善免疫抑制微環(huán)境發(fā)揮作用;CAR-T細(xì)胞在清除腫瘤細(xì)胞的同時(shí)也會(huì)殺傷表達(dá)相同靶點(diǎn)的正常細(xì)胞;針對除B細(xì)胞腫瘤之外的血液腫瘤以及實(shí)體瘤而言,CAR-T細(xì)胞的有效性還有待提高。本文重點(diǎn)介紹如何通過CAR-T細(xì)胞結(jié)構(gòu)的優(yōu)化使得CAR-T細(xì)胞能夠精準(zhǔn)地識別腫瘤細(xì)胞,克服腫瘤的免疫抑制微環(huán)境來提高CAR-T細(xì)胞治療惡性腫瘤的有效性;同時(shí)使得CAR-T細(xì)胞可以被更好地控制,使得CAR-T細(xì)胞的安全性更高。
[Abstract]:The chimeric antigen receptor T(chimeric antigen receptor T cells (T(chimeric receptor T cells) cells have moved from laboratory to clinical trial, and have achieved remarkable curative effect in the treatment of B cell malignant tumor, but in exploring the clinical study of CAR-T cell therapy for malignant tumor,There are still many difficulties and challenges: it is difficult to find tumor-specific targets to overcome their off-target off tumor effectts, and it is difficult for CAR-T cells to reach the tumor site in the treatment of solid tumors.In order to improve the immunosuppressive microenvironment, CAR-T cells can kill the normal cells with the same target while clearing the tumor cells.The effectiveness of CAR-T cells is still to be improved for blood tumors and solid tumors other than B-cell tumors.This paper focuses on how to optimize the structure of CAR-T cells so that CAR-T cells can accurately identify tumor cells and overcome tumor immunosuppressive microenvironment to improve the effectiveness of CAR-T cells in the treatment of malignant tumors.At the same time, CAR-T cells can be better controlled, making CAR-T cells more secure.
【作者單位】： 解放軍第307醫(yī)院造血干細(xì)胞移植科全軍造血干細(xì)胞研究所;
【基金】：首都臨床特色應(yīng)用研究與成果推廣項(xiàng)目(No.Z161100000516184)~~
【分類號】：R730.51
，

本文編號：1751536